COSMEGEN POWDER FOR SOLUTION

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

DACTINOMYCIN

Mevcut itibaren:

RECORDATI RARE DISEASES CANADA INC

ATC kodu:

L01DA01

INN (International Adı):

DACTINOMYCIN

Doz:

0.5MG

Farmasötik formu:

POWDER FOR SOLUTION

Kompozisyon:

DACTINOMYCIN 0.5MG

Uygulama yolu:

INTRAVENOUS

Paketteki üniteler:

0.5MG/VIAL

Reçete türü:

Prescription

Terapötik alanı:

ANTINEOPLASTIC AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0105865001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2006-09-06

Ürün özellikleri

_ _
_ _
_Page 1 of 23_
PRODUCT MONOGRAPH
PR COSMEGEN®
DACTINOMYCIN FOR INJECTION
LYOPHILIZED POWDER FOR INJECTION CONTAINING 500 MCG DACTINOMYCIN/VIAL
ACTINOMYCIN ANTIBIOTIC; ANTINEOPLASTIC
Recordati Rare Diseases Canada Inc.
3080 Yonge Street, Suite 6060
Toronto, ON
M4N 3N1
Control # 217570
Date of Revision:
August 29, 2018
_ _
_ _
_Page 2 of 23_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
..............................